MIRA Pharmaceuticals Inc. - שווי שוק בספרים MIRA

MIRA Pharmaceuticals (MIRA) develops synthetic cannabinoid substitutes for the therapy of neurological disorders and the management of pain syndromes. Current price action, recorded at 0.01, accompanies the company, whose future market dominance relies on the patent protection of unique formulas. However, the business currently generates no revenue as it undergoes clinical trial stages, which temporarily precludes the possibility of exercising pricing power.

This indicator reflects the net asset value, allowing investors to track capital base dynamics and business resilience to external shocks in real time. Analyzing the balance sheet capital of MIRA Pharmaceuticals (MIRA) is critically important, as in the absence of revenue, this resource determines the company's ability to fund costly clinical trials for new cannabinoid drugs.